Checkpoint blockade after kidney transplantation

Mathieu Lesouhaitier; Caroline Dudreuilh; Mathilde Tamain; Nada Kanaan; Elodie Bailly; Delphine Legoupil; Clement Deltombe; Peggy Perrin; Guillaume Manson; Cécile Vigneau; Roch Houot

doi:10.1016/j.ejca.2018.03.019

Checkpoint blockade after kidney transplantation

Eur J Cancer. 2018 Jun:96:111-114. doi: 10.1016/j.ejca.2018.03.019. Epub 2018 Apr 26.

Authors

Affiliations

¹ CHU Pontchaillou, Division of Nephrology, Rennes, France.
² Department of Nephrology and Renal Transplantation, Institut Francilien de Recherche en Néphrologie et Transplantation (IFRNT), Groupe Hospitalier Henri-Mondor/Albert-Chenevier, AP-HP (Assistance Publique-Hôpitaux de Paris), Créteil, France; DHU (Département Hospitalo-Universitaire), VIC (Virus-Immunité-Cancer), Université Paris-Est-Créteil (UPEC), IMRB (Institut Mondor de Recherche Biomédicale), Equipe 21, INSERM U 955, Créteil, France.
³ Division of Nephrology, CHU Clermont-Ferrand, Clermont-Ferrand, France; Université Clermont Auvergne, Clermont-Ferrand, France.
⁴ Division of Nephrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
⁵ Department of Nephrology and Kidney Transplantation, University Hospital of Tours, France; Université François Rabelais, Tours, France.
⁶ Division of Dermatology, Hôpital Morvan, CHU BREST, France.
⁷ Institute for Transplantation, Urology and Nephrology (ITUN), Nantes University Hospital, Nantes, France.
⁸ Nephrology-Transplantation Department, University Hospital, Strasbourg, France.
⁹ CHU Pontchaillou, Department of Hematology, Rennes, France.
¹⁰ CHU Pontchaillou, Division of Nephrology, Rennes, France; Univ Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR 1085, Rennes, France.
¹¹ CHU Pontchaillou, Department of Hematology, Rennes, France; INSERM, U1236, Rennes, France. Electronic address: roch.houot@chu-rennes.fr.

PMID: 29705511
DOI: 10.1016/j.ejca.2018.03.019

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents, Immunological / therapeutic use*
B7-H1 Antigen / antagonists & inhibitors*
B7-H1 Antigen / immunology
CTLA-4 Antigen / antagonists & inhibitors
CTLA-4 Antigen / immunology
Female
Graft Rejection / immunology
Graft Rejection / prevention & control
Graft Survival / drug effects
Humans
Immunosuppressive Agents / adverse effects
Ipilimumab / therapeutic use
Kidney Transplantation / adverse effects*
Kidney Transplantation / mortality
Male
Middle Aged
Neoplasms / drug therapy*
Neoplasms / immunology
Neoplasms / mortality
Neoplasms / pathology
Nivolumab / therapeutic use
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Programmed Cell Death 1 Receptor / immunology
Risk Factors
Time Factors
Treatment Outcome

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
B7-H1 Antigen
CD274 protein, human
CTLA-4 Antigen
CTLA4 protein, human
Immunosuppressive Agents
Ipilimumab
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Nivolumab
pembrolizumab
avelumab